Key result
Implantable cardioverter defibrillator (ICD) utilization for patients meeting Class I indications was only one-third of the expected rate despite near-perfect pharmacologic treatment.
Answers are grounded in this paper and cite their sources.
This editorial emphasizes the significant underutilization of ICDs in eligible heart failure patients and discusses the complex regulatory and guideline landscape contributing to this issue.
Over 5 million individuals are afflicted with heart failure in the United States per year.[1] Current guidelines based on the MADIT-I and II, MUSTT and SCDHeFT trials recommend the use of pharmacologic as well as implantable cardioverter defibrillator (ICD) therapy as Class I indications for the prevention of sudden cardiac death (SCD) in a subgroup of patients (depending on their ejection fraction, NYHA class, and a variety of other parameters).[2-7] However, despite these guidelines, the use of ICDs has been reported as suboptimal in prior publications as well as in the article by Pillarisetti, et al in this issue of the Journal.[8] Pillarisetti, et al present the current state of ICD use in their single center experience, noting profound underutilization of ICDs as a prophylactic treatment for sudden cardiac death.[8] They subsequently went on to carefully examine the reasons behind ICD underuse.In their retrospective study, they found that though pharmacologic treatment of SCD with a betablocker, angiotensin cardioverter enzyme inhibitory/angiotensin receptor blocker (ACE/ARB), diuretics and aldosterone antagonists (AA) was nearly perfect, the implementation of ICDs for treatment of patients who met ICD Class I indications was only 1/3 of the expected rate.[2] Over-or under-utilization?Prior to delving into the data, it is important to put into perspective the last several years in electrophysiology which have proven complicated for many ICD implanters.After Al-Khatib, et al suggested a high rate of inappropriate ICD implantation in the United Stated, investigations by the Department of Justice into the practice patterns of implanting centers became more common.[9-11] However, one clear limitation of that seminal publication was precisely how "appropriateness" was defined -namely by criteria advanced by Medicare/insurers rather than strictly abiding by guidelines.The issue at hand is that, while all legislation to identify appropriate versus inappropriate is well-meaning, the number of different guidelines to which physicians must refer is extensive and can prove to be near
No takes yet. Share an insight, caveat, or question.
Gaba et al. (2015) conducted an editorial in Heart failure and sudden cardiac death. Implantable cardioverter defibrillator (ICD) was evaluated. Implantable cardioverter defibrillator (ICD) utilization for patients meeting Class I indications was only one-third of the expected rate despite near-perfect pharmacologic treatment.
Synapse has enriched 10 related papers. Consider them for comparative context: